2019台灣生技月 Bio Taiwan 生物科技大展

2019 台灣生技月 南港展覽館

同期會議

Academia Bio-Innotech Presentation

 


Taiwan possesses both strong biotech talent and a solid R&D base. As PhrMA posted in 2017, Taiwan is ranked 3rd among 21 emerging countries for its biotech efforts, in particular in the fields of basic infrastructure, practical research and copyright protection.
 
To raise the value of innovative research discoveries, the BioMed Commercialization Center (Drug Division, BMCC|Drug) was set up by the Taiwan government with the mission to optimize drug commercialization processes for academic and industry clients in Taiwan. With Bio Asia Taiwan being one of the largest annual biotech events in Asia, BMCC|Drug is delighted to be taking part to bring Taiwan biotechnology innovations—Bio-Innotechs—to this gathering of bio-industry professionals from Asia and around the world to seek collaboration, licensing and investment opportunities.


Organizer: BioMed Commercialization Center (Drug Division, BMCC|Drug)


Date: July 25th (Thu), 2019


Venue: Rm 402a, 4F, Taipei Nangang Exhibition Center, Hall 1 (TNEC1)
(No.1, Jingmao 2nd Rd., Nangang District, Taipei, Taiwan)


Registration: Registration is free of charge. However, the organizer reserves the right to change the event program and decide upon admitting participants.
 
Please register by JULY 23th via the following link: https://lihi.cc/Soklb

 


 

Time

Topic

Presenter

13:00-13:30

Registration

13:30-13:40

Opening Remarks

Chi-Feng Chang,
Vice President,
Development Center for Biotechnology

13:40-13:55

Universal Antibody Lock to Enhance Antidrug Drug Selectivity and Safety

Tian-Lu Cheng,
Professor,
Kaohsiung Medical University

13:55-14:10

Development of WYC-0209-241 as GSTO Inhibitor for Cancer Therapy

Yang-Chang Wu,
Chair Professor,
China Medical University

14:10-14:25

The Novel αIIbβ3 Antagonist TMV-7 and Its Derivative RR Prevent Thrombosis without the Risk of Bleeding

Tur-Fu Huang,
Emeritus Professor,
Mackay Medical College

14:25-14:40

High Yielding CHO Cell Expression System

Hsin-Lin Lu,
Research Fellow,
Development Center for Biotechnology

14:40-14:55

Quantity and Quality Controlled Bioprocess of Chimeric Antigen Receptor (CAR)-T Cells

Hsin-Lin Lu,
Research Fellow,
Development Center for Biotechnology

14:55-15:10 Adenosine Augmentation Compounds for the Treatment of Neurodegenerative Diseases Yijuang Chern,
Distinguished Research Fellow,
Academia Sinica

15:10-15:20

Break

15:20-15:35

A New Combinational Treatment Method of TMG/DMG with Ketamine for Psychiatric Disorders

Hwei-Hsien Chen,
Investigator,
National Health Research Institutes

15:35-15:50

Highly Selective HDAC6 Inhibitor, MPT0G211, in Multiple Myeloma and Alzheimer's Disease

Shiow-Lin Pan,
Professor,
Taipei Medical University

15:50-16:05

Development of Antibody Drug AP001 against a Novel Tumor Marker Protein AP for Human Cancer Treatment

Wei-Chun HuangFu,
Assistant Professor,
Taipei Medical University

16:05-16:20

Selective Topo-II Chemotherapeutics

Tsai-Kun Li,
Professor,
National Taiwan University

16:20-16:35

Customizable Particles to Enhance the Immunogenicity of Peptide-based T Cell Vaccines

Che-Ming Hu,
Assistant Research Fellow,
Academia Sinica

16:35-16:50 Development of Anti-lung Cancer Peptide Drug Jinghua Tsai Chang,
Assistant Professor,
Chung Shan Medical University

16:50-17:00

Closing